Firma Ewopharma, Autor bei PR-Web

Ewopharma and Purpose Pharma Announce a Strategic Partnership for the Commercialization of Attrogy in Selected Central and Eastern European Countries

Posted on 12. October 2026 by Firma Ewopharma Posted in General Tagged Attrogy, Central and Eastern European, commercial partnership, commercialization, cross-border distribution, European Medicines Agency approval, medical commercialization, neurological disorders, neuropathy treatment, orphan drug strategy, patient access expansion, rare disease portfolio, rare diseases, specialty pharmaceuticals, strategic collaboration

Ewopharma is pleased to announce that it has entered into a strategic collaboration with Purpose Pharma for the commercialization of Attrogy® (diflunisal) in selected Central and Eastern European (CEE) countries. The partnership aims to expand patient access to this important […]

Ewopharma and Protina – Strengthening the Presence of Diasporal® and Basica® in Bulgaria with a new partnership

Posted on 7. July 2026 by Firma Ewopharma Posted in General Tagged basica, company, diasporal, ewopharma, flaschker, market, mineral, network, new, organic, production, protina, research, strong, with

Ewopharma AG and Protina Pharmazeutische GmbH announce their new distribution partnership for Bulgaria. Ewopharma takes over market access and the targeted promotion of Protina’s brands Diasporal® and Basica® – two consumer health brands already established in Bulgaria. Building on its […]

Ewopharma and Dr. Falk Pharma renew their long-standing partnership – a commitment built to last

Posted on 29. May 2026 by Firma Ewopharma Posted in General Tagged board, clinical, company, disease, ewopharma, falk, freiburg, health, market, network, new, patients, research, strong, with

Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues to manage market access and the targeted promotion of Dr. […]

Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC

Posted on 16. April 2026 by Firma Ewopharma Posted in General Tagged cancer, cell, cells, cstone, egfr, esmo, ewopharma, market, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. This recommendation supports sugemalimab for […]

Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication

Posted on 17. December 202522. December 2025 by Firma Ewopharma Posted in General Tagged alk, cancer, cell, cells, chemoradiotherapy, cstone, egfr, ewopharma, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a new indication for sugemalimab as monotherapy for adult patients with […]

Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria

Posted on 15. April 202511. April 2025 by Firma Ewopharma Posted in General Tagged balloon, coatings, dcb, eluting, ewopharma, healthcare, market, medical, patients, restenosis, solutions, translumina, treatment, vessel, with

Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES […]

AllergyCare AG Becomes Part Of Ewopharma Group

Posted on 3. June 20243. June 2024 by Firma Ewopharma Posted in General Tagged aida, business, company, customers, ewopharma, health, healthcare, home, market, new, pharmaceutical, privileged, services, treatment, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention […]

Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland

Posted on 27. May 202427. May 2024 by Firma Ewopharma Posted in General Tagged cancer, cee, cell, clinical, ewopharma, lymphoma, medical, new, nsclc, patients, payment, research, revenues, treatment, with

Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights […]

Neomed s.r.o. becomes part of Ewopharma Group

Posted on 31. May 2023 by Firma Ewopharma Posted in General Tagged company, cosmetic, devices, ewopharma, healthcare, intraocular, lenses, logistics, market, medical, new, patients, pharmaceutical, services, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, […]